SCHEMBL13311658

SCHEMBL13311658

CCCCCC/C=C\CCCCCc1cccc(O)c1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 3/20 1.00
F3 P13726 3/20 1.00
MMP2 P08253 2/20 1.00
SAE1 Q9UBE0 2/20 1.00
KDM4E B2RXH2 1/20 1.00
MAPT P10636 1/20 1.00
ALOX15 P16050 1/20 1.00
ECE1 P42892 1/20 1.00
SGMS1 Q86VZ5 1/20 1.00
SGMS2 Q8NHU3 1/20 1.00
MUS81 Q96NY9 1/20 1.00
HSD17B10 Q99714 1/20 1.00
BID P55957 7/20 0.95
MCL1 Q07820 7/20 0.95
BCL2L1 Q07817 6/20 0.95
BAK1 Q16611 6/20 0.95
KAT8 Q9H7Z6 4/20 0.84
EP300 Q09472 3/20 0.84
KAT5 Q92993 3/20 0.84
KAT2B Q92831 2/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5370295 1.00 F7 (1.00) F7F3MMP2SAE1KDM4E
SCHEMBL5394786 1.00 F7 (1.00) F7F3MMP2SAE1KDM4E
SCHEMBL5370300 1.00 F7 (1.00) F7F3MMP2SAE1KDM4E
Ginkgolic Acid 17:1 SCHEMBL5380765 1.00 F7 (1.00) F7F3MMP2SAE1KDM4E
Gingkolic Acid SCHEMBL163525 1.00 F7 (1.00) F7F3MMP2SAE1KDM4E
Ginkgolic Acid 17:1 SCHEMBL5380767 1.00 F7 (1.00) F7F3MMP2SAE1KDM4E
Ginkgolic Acid 17:1 SCHEMBL5380775 1.00 F7 (1.00) F7F3MMP2SAE1KDM4E
Gingkolic Acid SCHEMBL8040660 1.00 F7 (1.00) F7F3MMP2SAE1KDM4E
SCHEMBL5370293 1.00 F7 (1.00) F7F3MMP2SAE1KDM4E
Gingkolic Acid SCHEMBL8042802 1.00 F7 (1.00) F7F3MMP2SAE1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728043-B2 Methods for treatment of beta-amyloid protein-induced ocular disease KIM DARRICK S H L 2010-06-01 US disclosed
US-20070003641-A1 Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease KIM DARRICK S H 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070003641-A1 Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease APP, BACE1, GSAP F7 4476/4885F3 3129/4885MMP2 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.